Ad Code: Sarclisa - Display Banners Conference - FEB - 192478

The ASH Research Collaborative developed the COSMIC study to address the risks severe COVID-19 complications pose to patients with multiple myeloma.

Monoclonal antibody delayed progression to MM, improved PFS, ORR, and OS, and was well tolerated in high-risk SMM, supporting early intervention over monitoring.

This year’s ASH was exceptionally busy, with overlapping sessions, including three back-to-back myeloma talks. Key studies showcased practice-changing findings.

iMMagine-1 phase 2 trial shows 97% response, 62% complete response in relapsed/refractory myeloma, with strong safety and promising 2026 launch.

A recent study evaluated the impact of circulating plasma cells in patients with primary multiple myeloma on bortezomib-containing induction therapy.

Addition of elotuzumab to standard therapy in transplant-eligible patients with MM did not improve PFS or OS in the long-term follow-up of the GMMG-HD6 trial.

“This study reveals distinct immune subpopulations associated with specific myeloma cell genotypes and highlights the central role of ncRNAs in modulating the phenotypic and functional states of both malignant and non-malignant cells in the MM BMME,” the authors concluded.

Will you be attending “Newly Diagnosed Multiple Myeloma: Many Choices and More Questions” on Saturday, December 7?